LYNCH Biologics Closes on Transaction to Purchase GEM 21S(R) G...
FRANKLIN, Tennessee, Sept. 28, 2018 /PRNewswire-AsiaNet/ -- LYNCH Biologics LLC (LBIO) announced today that it has closed on a transaction with Luitpold Pharmaceuticals Inc. (LPI), under which LBIO has acquired all rights relating to GEM 21S Growth Factor Enhance Matrix, and certain additional assets relat...
Read more https://view-release/?pr-id=75468